The European Union’s medicines regulator said Friday it had started a “rolling review” of a COVID-19 vaccine developed by German firm CureVac, the first step towards a possible authorisation in the bloc. “Preliminary results from laboratory studies and early clinical studies in adults… suggest the vaccine triggers the production of antibodies and immune cells that